mRNA vaccine technology is not new, but there were no mRNA vaccines that had approval for use in humans until recently.
Some vaccines use a whole virus or bacterium to teach our bodies how to build up immunity to the pathogen. These pathogens are inactivated or attenuated, which means weakened. Other vaccines use parts of viruses or bacteria.
Recombinant vaccine technology employs yeast or bacterial cells to made many copies of a particular viral or bacterial protein or sometimes a small part of the protein.
mRNA vaccines bypass this step. They are chemically synthesized without the need for cells or pathogens, making the production process simpler. mRNA vaccines carry the information that allows our own cells to make the pathogen’s proteins or protein fragments themselves.
Importantly, mRNA vaccines only carry the information to make a small part of a pathogen. From this information, it is not possible for our cells to make the whole pathogen.
Both mRNA COVID-19 vaccines that Pfizer/BioNTech and Moderna have developed cannot cause COVID-19. They do not carry the full information for our cells to make the SARS-CoV-2 virus, and therefore, cannot cause an infection.
While the concept of mRNA vaccines may seem simple, the technology is rather sophisticated.
RNA is a notoriously fragile molecule. Delivering mRNA successfully to cells inside our bodies and ensuring that enzymes within our cells do not degrade it are key challenges in vaccine development.
Chemical modifications during the manufacturing process can significantly improve the stability of mRNA vaccines.
Encapsulating mRNA in lipid nanoparticles is one way to ensure that a vaccine can successfully enter cells and deliver the mRNA into the cytoplasm.
mRNA does not linger in our cells for long. Once it has passed its instructions to the protein-making machinery in our cells, enzymes called ribonucleases (RNases) degrade the mRNA.
It is not possible for mRNA to move into the nucleus of a cell as it lacks the signals that would allow it to enter this compartment. This means that RNA cannot integrate into the DNA of the vaccinated cell.
There is no risk of long-term genetic changes with mRNA vaccines.
The mRNA COVID-19 vaccines by Pfizer and Moderna have undergone safety testing in human clinical trials.
The United States Food and Drug Administration (FDA) have granted Emergency Use Authorization (EUA) for the Pfizer mRNA vaccine after reviewing the safety data from over 37,000 trial participants.
“The most commonly reported side effects, which typically lasted several days, were pain at the injection site, tiredness, headache, muscle pain, chills, joint pain, and fever,” the FDA wrote in their statement. “Of note, more people experienced these side effects after the second dose than after the first dose, so it is important for vaccination providers and recipients to expect that there may be some side effects after either dose, but even more so after the second dose.”
Rumours took hold in March when Mr Gates said in an interview that eventually “we will have some digital certificates” which would be used to show who’d recovered, been tested and ultimately who received a vaccine. He made no mention of microchips.
This led to one widely shared article headlined: “Bill Gates will use microchip implants to fight coronavirus.”
The article makes reference to a study, funded by The Gates Foundation, into a technology that could store someone’s vaccine records in a special ink administered at the same time as an injection.
However, the technology is not a microchip and is more like an invisible tattoo. It has not been rolled out yet, would not allow people to be tracked and personal information would not be entered into a database, says Ana Jaklenec, a scientist involved in the study.
Aborted baby cells (Fetus tissue claims)
The developers of the vaccine at Oxford University say they worked with cloned cells, but these cells “are not themselves the cells of aborted babies”.
oct 2020 dna vac was just allowed
Freedom of taking the Vaccine
Vaccines and Related Biological Products Advisory Committee Meeting
December 17, 2020
FDA Briefing Document
Moderna COVID-19 Vaccine
Throughout the safety follow-up period to date, there were three reports of facial paralysis (Bell’s palsy) in the vaccine group and one in the placebo group. Currently available information is insufficient to determine a causal relationship with the vaccine. There were no other notable patterns or numerical imbalances between treatment groups for specific categories of adverse events (including other neurologic, neuroinflammatory, and thrombotic events) that would suggest a causal relationship to mRNA-1273. The frequency of serious adverse events was low (1.0% in the mRNA-1273 arm and 1.0% in the placebo arm), without meaningful imbalances between study arms. The most common SAEs in the vaccine group which were numerically higher than the placebo group were myocardial infarction (0.03%), cholecystitis (0.02%), and nephrolithiasis (0.02%), although the small numbers of cases of these events do not suggest a causal relationship. The most common SAEs in the placebo arm which were numerically higher than the vaccine arm, aside from COVID-19 (0.1%), were pneumonia (0.05%) and pulmonary embolism (0.03%). With the exception of more frequent, generally mild to moderate reactogenicity in participants <65 years of age, the safety profile of mRNA-1273 was generally similar across age groups, genders, ethnic and racial groups, participants with or without medical comorbidities, and participants with or without evidence of prior SARS-CoV-2 infection at enrollment. This meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) is being convened to discuss and provide recommendations on whether, based on the totality of scientific evidence available, the benefits of the mRNA-1273 COVID-19 Vaccine outweigh its risks for use in individuals 18 years of age and older. The committee will also discuss what additional studies should be conducted by the vaccine manufacturer following issuance of the EUA to gather further data on the safety and effectiveness of this vaccine.